Diagnostic Consultative Center (DCC) "Sveta Anna" EOOD
- Address
- Ulitsa Dimitir Mollov 1, 1750 Sofia, Bulgaria
Cardiovascular Diseases
At the Diagnostic Consultative Center Sveta Anna, investigators are conducting studies focused on preventing and treating major heart conditions such as acute coronary syndrome, myocardial infarction, and atrial fibrillation. The trials aim to evaluate new therapies that reduce cardiovascular events and improve long‑term outcomes.
- Evaluation of novel lipid‑lowering agents
- Testing oral anticoagulant alternatives for stroke prevention
- Assessing anti‑inflammatory monoclonal antibodies in post‑MI patients
- Investigating rapid‑action treatments for suspected heart attacks
The DCC “Sveta Anna” collaborates with regional hospitals to enroll high‑risk patients across Bulgaria.
Immune System Diseases
Research at the center includes trials in autoimmune disorders such as systemic lupus erythematosus and IgA nephropathy. These studies test targeted agents that aim to lower disease activity and protect kidney function while monitoring safety.
- Assessing efficacy of selective S1P‑modulators in lupus
- Evaluating monoclonal antibodies that reduce proteinuria in IgA nephropathy
- Long‑term safety monitoring of immune‑modulating therapies
- Exploring biomarkers of inflammation for treatment response
Eight investigators lead these projects, integrating immunology expertise with cardiometabolic research.
Nutritional and Metabolic Diseases
The site’s metabolic program addresses conditions like obesity and type 2 diabetes associated with cardiovascular risk. Trials seek to determine whether new agents can improve weight management, glycemic control, and reduce related heart complications.
- Testing novel weight‑loss compounds in obese adults
- Evaluating impact of lipid‑lowering therapy on diabetic patients
- Studying renal outcomes in metabolic syndrome
- Investigating combined lifestyle and pharmacologic interventions
Located on Ulitsa Dimitir Mollov 1 in Sofia, the center provides convenient access for participants from across the region.
Respiratory Tract Diseases
Investigations include pulmonary hypertension and related heart‑lung interactions, such as pulmonary arterial hypertension and PH‑HFpEF. The goal is to test drugs that improve exercise capacity, lower pulmonary pressures, and delay disease progression.
- Assessing oral and inhaled therapies for PAH
- Evaluating impact of treatments on pulmonary vascular resistance
- Measuring functional improvement with six‑minute walk test
- Safety profiling of combination regimens in PH‑HFpEF
The DCC works with cardiology and pulmonology units to ensure comprehensive patient care.
Miscellaneous Research
A subset of studies at the center explores cross‑disciplinary conditions that do not fit a single therapeutic category, including high‑risk transient ischemic attack and systemic inflammation linked to chronic kidney disease. These trials aim to identify broad‑acting strategies that lower overall cardiovascular risk.
- Investigating anti‑IL‑6 antibodies for combined heart and kidney protection
- Testing clot‑prevention agents after acute stroke
- Evaluating novel biomarkers for early detection of vascular events
- Long‑term follow‑up of participants in multiple disease cohorts
With a portfolio of 30 clinical trials, the center leverages eight investigators to advance innovative therapies for diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 61 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 61 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Novartis Pharma AG1active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG6trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic Consultative Center (DCC) "Sveta Anna" EOOD
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 61 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.